BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

513 related articles for article (PubMed ID: 30853582)

  • 1. Molecular chaperones biochemistry and role in neurodegenerative diseases.
    Chaari A
    Int J Biol Macromol; 2019 Jun; 131():396-411. PubMed ID: 30853582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular chaperones and neuronal proteostasis.
    Smith HL; Li W; Cheetham ME
    Semin Cell Dev Biol; 2015 Apr; 40():142-52. PubMed ID: 25770416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hsp90 and Its Co-Chaperones in Neurodegenerative Diseases.
    Bohush A; Bieganowski P; Filipek A
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31600883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of molecular chaperones in neurodegenerative disorders.
    Meriin AB; Sherman MY
    Int J Hyperthermia; 2005 Aug; 21(5):403-19. PubMed ID: 16048838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Underlying mechanisms and chemical/biochemical therapeutic approaches to ameliorate protein misfolding neurodegenerative diseases.
    Hekmatimoghaddam S; Zare-Khormizi MR; Pourrajab F
    Biofactors; 2017 Nov; 43(6):737-759. PubMed ID: 26899445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenging Proteostasis: Role of the Chaperone Network to Control Aggregation-Prone Proteins in Human Disease.
    Sinnige T; Yu A; Morimoto RI
    Adv Exp Med Biol; 2020; 1243():53-68. PubMed ID: 32297211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo aspects of protein folding and quality control.
    Balchin D; Hayer-Hartl M; Hartl FU
    Science; 2016 Jul; 353(6294):aac4354. PubMed ID: 27365453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein folding, misfolding and quality control: the role of molecular chaperones.
    Papsdorf K; Richter K
    Essays Biochem; 2014; 56():53-68. PubMed ID: 25131586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Walking the tightrope: proteostasis and neurodegenerative disease.
    Yerbury JJ; Ooi L; Dillin A; Saunders DN; Hatters DM; Beart PM; Cashman NR; Wilson MR; Ecroyd H
    J Neurochem; 2016 May; 137(4):489-505. PubMed ID: 26872075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting chaperones, heat shock factor-1, and unfolded protein response: Promising therapeutic approaches for neurodegenerative disorders.
    Bose S; Cho J
    Ageing Res Rev; 2017 May; 35():155-175. PubMed ID: 27702699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular chaperone dysfunction in neurodegenerative diseases and effects of curcumin.
    Maiti P; Manna J; Veleri S; Frautschy S
    Biomed Res Int; 2014; 2014():495091. PubMed ID: 25386560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Chaperones in Neurodegenerative Diseases: A Short Review.
    Bobori C; Theocharopoulou G; Vlamos P
    Adv Exp Med Biol; 2017; 987():219-231. PubMed ID: 28971461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging Targets and Latest Proteomics Based Therapeutic Approaches in Neurodegenerative Diseases.
    Fatima MT; Islam Z; Ahmad E; Salahuddin P
    Curr Protein Pept Sci; 2018; 19(9):858-875. PubMed ID: 28762306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chaperones in Neurodegeneration.
    Lindberg I; Shorter J; Wiseman RL; Chiti F; Dickey CA; McLean PJ
    J Neurosci; 2015 Oct; 35(41):13853-9. PubMed ID: 26468185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality control of the proteins associated with neurodegenerative diseases.
    Gao X; Hu H
    Acta Biochim Biophys Sin (Shanghai); 2008 Jul; 40(7):612-8. PubMed ID: 18604452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conformational changes and aggregation of expanded polyglutamine proteins as therapeutic targets of the polyglutamine diseases: exposed beta-sheet hypothesis.
    Nagai Y; Popiel HA
    Curr Pharm Des; 2008; 14(30):3267-79. PubMed ID: 19075705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aggregopathy in neurodegenerative diseases: mechanisms and therapeutic implication.
    Dohm CP; Kermer P; Bähr M
    Neurodegener Dis; 2008; 5(6):321-38. PubMed ID: 18309232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of molecular chaperones as a therapeutic strategy for the polyglutamine diseases.
    Nagai Y; Fujikake N; Popiel HA; Wada K
    Curr Pharm Biotechnol; 2010 Feb; 11(2):188-97. PubMed ID: 20166962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. When proteostasis goes bad: Protein aggregation in the cell.
    Radwan M; Wood RJ; Sui X; Hatters DM
    IUBMB Life; 2017 Feb; 69(2):49-54. PubMed ID: 28066979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of HSP70 and its co-chaperones in protein misfolding, aggregation and disease.
    Duncan EJ; Cheetham ME; Chapple JP; van der Spuy J
    Subcell Biochem; 2015; 78():243-73. PubMed ID: 25487025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.